Smith & Nephew PLC (LSE:SN) — Market Cap & Net Worth
Market Cap & Net Worth: Smith & Nephew PLC (SN)
Smith & Nephew PLC (LSE:SN) has a market capitalization of $116.81 Million (GBX960.05 Billion) as of June 16, 2026. Listed on the LSE stock exchange, this UK-based company holds position #18704 globally and #106 in its home market, demonstrating a -1.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Smith & Nephew PLC's stock price GBX1131.00 by its total outstanding shares 848850481 (848.85 Million). Review debt load of Smith & Nephew PLC to assess the company's total debt and financial obligations.
Smith & Nephew PLC Market Cap History: 2015 to 2026
Smith & Nephew PLC's market capitalization history from 2015 to 2026. Data shows growth from $97.40 Million to $116.81 Million (2.18% CAGR).
Index Memberships
Smith & Nephew PLC is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$67.61 Billion | 0.17% | #59 of 573 |
|
FTSE 350
FTLC
|
$67.21 Billion | 0.17% | #57 of 350 |
|
FTSE 100 Index (UK)
FTSE
|
$55.34 Billion | 0.21% | #50 of 100 |
|
STOXX Europe Large 200 EUR Price
LCXP
|
$7.18 Trillion | 0.00% | #148 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$7.18 Trillion | 0.00% | #148 of 182 |
|
FTSE 350 Health Care Equipment & Services
NMX4530
|
$175.75 Million | 66.46% | #1 of 3 |
Weight: Smith & Nephew PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Smith & Nephew PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Smith & Nephew PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Smith & Nephew PLC's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.20x
Smith & Nephew PLC's market cap is 0.20 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $100.36 Million | $4.67 Billion | $784.00 Million | 0.02x | 0.13x |
| 2017 | $108.07 Million | $4.76 Billion | $767.00 Million | 0.02x | 0.14x |
| 2018 | $126.27 Million | $4.90 Billion | $663.00 Million | 0.03x | 0.19x |
| 2019 | $161.62 Million | $5.14 Billion | $600.00 Million | 0.03x | 0.27x |
| 2020 | $136.72 Million | $4.56 Billion | $448.00 Million | 0.03x | 0.31x |
| 2021 | $120.43 Million | $5.21 Billion | $524.00 Million | 0.02x | 0.23x |
| 2022 | $106.77 Million | $5.21 Billion | $223.00 Million | 0.02x | 0.48x |
| 2023 | $107.56 Million | $5.55 Billion | $263.00 Million | 0.02x | 0.41x |
| 2024 | $102.39 Million | $5.81 Billion | $412.00 Million | 0.02x | 0.25x |
| 2025 | $127.91 Million | $6.29 Billion | $638.11 Million | 0.02x | 0.20x |
Competitor Companies of SN by Market Capitalization
Companies near Smith & Nephew PLC in the global market cap rankings as of June 16, 2026.
Key companies related to Smith & Nephew PLC by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #151 globally with a market cap of $154.19 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #205 globally with a market cap of $117.85 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #237 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #245 globally with a market cap of $103.20 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #151 | Abbott Laboratories | NYSE:ABT | $154.19 Billion | $88.67 |
| #205 | Stryker Corporation | NYSE:SYK | $117.85 Billion | $307.94 |
| #237 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #245 | Medtronic PLC | NYSE:MDT | $103.20 Billion | $80.38 |
Smith & Nephew PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Smith & Nephew PLC's market cap moved from $97.40 Million to $ 116.81 Million, with a yearly change of 2.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX116.81 Million | -8.68% |
| 2025 | GBX127.91 Million | +24.92% |
| 2024 | GBX102.39 Million | -4.80% |
| 2023 | GBX107.56 Million | +0.74% |
| 2022 | GBX106.77 Million | -11.35% |
| 2021 | GBX120.43 Million | -11.91% |
| 2020 | GBX136.72 Million | -15.41% |
| 2019 | GBX161.62 Million | +28.00% |
| 2018 | GBX126.27 Million | +16.84% |
| 2017 | GBX108.07 Million | +7.69% |
| 2016 | GBX100.36 Million | +3.03% |
| 2015 | GBX97.40 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Smith & Nephew PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.81 Million USD |
| MoneyControl | $116.81 Million USD |
| MarketWatch | $116.81 Million USD |
| marketcap.company | $116.81 Million USD |
| Reuters | $116.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Smith & Nephew PLC
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; t… Read more